 |
3 Diseases |  |
0 Trials |
|
0 Trials |  |
58 News |  |
| 12» |
- || velsecorat (AZD7594) / AstraZeneca
Clinical, PK/PD data, Journal: Characterization of clinical ADME and pharmacokinetics of velsecorat using an intravenous microtracer combined with an inhaled dose in healthy subjects. (Pubmed Central) - Apr 5, 2022
This study provides a comprehensive assessment of the disposition of velsecorat in humans. It also highlights a number of complexities associated with determining human absorption, distribution, metabolism and excretion for velsecorat, related to the inhaled route, the high metabolic clearance, sequential metabolite formation and the low intravenous dose.
- || velsecorat (AZD7594) / AstraZeneca
PK/PD data, Journal: Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers. (Pubmed Central) - Apr 5, 2022
The early clinical evaluation of inhaled velsecorat suggests that this novel SGRM is well tolerated in the dose range investigated. It shows dose proportional plasma exposure, low accumulation, and has dose-dependent effects on markers of glucocorticoid activity.
- velsecorat (AZD7594) / AstraZeneca
[VIRTUAL] Results and Learnings from AMBER, a Decentralized Phase I Study Assessing the Pharmacokinetic and Pharmacodynamic Profile of Inhaled Velsecorat, a Non-Steroidal, Selective Glucocorticoid Receptor Modulator, in Adolescents with Asthma () - Mar 14, 2021 - Abstract #ATS2021ATS_2602;
P1
AMBER offered a convenient and patient-centric study experience for adolescents and their families during the pandemic. Decentralized studies has the potential to become a new standard by offering a flexible convenient, safe and patient-friendly study format for an adolescent population, as shown by the high recruitment and retention rate during the peak of the COVID-19 pandemic.
- velsecorat (AZD7594) / AstraZeneca, Veramyst (fluticasone furoate nasal spray) / GSK
[VIRTUAL] Results of a Phase 2b Dose Finding Study of Velsecorat, an Inhaled Non-Steroidal, Selective Glucocorticoid Receptor Modulator in Asthma (GRANIT) () - Mar 14, 2021 - Abstract #ATS2021ATS_2186;
P2b
Conclusions Velsecorat improved lung function and reduced time to first event and annual rate of CompEx events vs PBO. Primary endpoint results were likely influenced by the large proportion of early discontinuations on the PBO arm.
- velsecorat (AZD7594) / AstraZeneca, Veramyst (fluticasone furoate nasal spray) / GSK
[VIRTUAL] Velsecorat (AZD7594), a Selective Glucocorticoid Receptor Modulator (SGRM) Demonstrates Favorable Pre-Clinical Efficacy vs Safety Profile Compared to Current Clinical Inhaled Steroid, Fluticasone Furoate () - Mar 14, 2021 - Abstract #ATS2021ATS_286;
These exciting data suggest that velsecorat, when dosed appropriately, possesses the beneficial effects of ICS with fewer of the side-effects that plague this class of compound. velsecorat, currently in phase 2 clinical trials, represents a new therapeutic opportunity for patients with asthma.
- || GSK870086 inhalation / GSK, velsecorat (AZD7594) / AstraZeneca, AZD5423 / AstraZeneca
Review, Journal: Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review. (Pubmed Central) - Sep 30, 2020
Several compounds are currently under pre-clinical development, but only three novel experimental GR agonists (GW870086X, AZD5423, AZD7594) seem to have some potential therapeutic relevance and have entered clinical trials for the treatment of asthma. Since data from pre-clinical studies have not always been confirmed in clinical investigations, well-designed randomized controlled trials are needed in asthmatic patients to confirm the potentially positive benefit/risk ratio of each specific SEGRA and to optimize the development strategy of these agents in respiratory medicine.
- || velsecorat (AZD7594) / AstraZeneca
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: AMBER: A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma (clinicaltrials.gov) - Aug 19, 2020
P1, N=34, Completed, Sponsor: AstraZeneca
Since data from pre-clinical studies have not always been confirmed in clinical investigations, well-designed randomized controlled trials are needed in asthmatic patients to confirm the potentially positive benefit/risk ratio of each specific SEGRA and to optimize the development strategy of these agents in respiratory medicine. Recruiting --> Completed | N=24 --> 34 | Trial completion date: Nov 2020 --> Jul 2020 | Trial primary completion date: Nov 2020 --> Jul 2020
- | velsecorat (AZD7594) / AstraZeneca
Journal: Stereoretentive Etherification of an α-aryl-β-amino-alcohol using a Selective Aziridinium Ring Opening for the Synthesis of AZD7594. (Pubmed Central) - Jul 8, 2020
Process analytical techniques were used to establish reaction understanding and mixing on large scale was modelled in silico. The process provided a selective and efficient method of preparing the non-steroidal, inhaled selective glucocorticoid receptor modulator, AZD7594.
- velsecorat (AZD7594) / AstraZeneca
[VIRTUAL] Design of a Phase 1 Virtual Hybrid Study of AZD7594, an Inhaled Non-Steroidal, Selective Glucocorticoid Receptor Modulator, in Adolescents with Asthma (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_4604;
P2b
Conclusion The results of this study will characterize the PK, PD and safety of AZD7594 in adolescents with GINA 2 asthma. The hybrid virtual study concept will provide detailed insight into the feasibility of similar designs in this age group.
- || velsecorat (AZD7594) / AstraZeneca
Clinical, PK/PD data, Journal: Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers. (Pubmed Central) - Jun 8, 2020
In conclusion, the early clinical evaluation of inhaled AZD7594 suggests that this novel SGRM is well tolerated in the dose range investigated and also in a Japanese population. It shows dose-proportional plasma exposure, moderate accumulation and has limited impact on systemic markers of glucocorticoid activity.
- || velsecorat (AZD7594) / AstraZeneca
Enrollment open, Trial completion date, Trial primary completion date: AMBER: A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma (clinicaltrials.gov) - May 14, 2020
P1, N=24, Recruiting, Sponsor: AstraZeneca
It shows dose-proportional plasma exposure, moderate accumulation and has limited impact on systemic markers of glucocorticoid activity. Active, not recruiting --> Recruiting | Trial completion date: Jun 2020 --> Nov 2020 | Trial primary completion date: Jun 2020 --> Nov 2020
- || velsecorat (AZD7594) / AstraZeneca
Enrollment closed: AMBER: A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma (clinicaltrials.gov) - Apr 3, 2020
P1, N=24, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Recruiting | Trial completion date: Jun 2020 --> Nov 2020 | Trial primary completion date: Jun 2020 --> Nov 2020 Recruiting --> Active, not recruiting
- AZD7594 / AstraZeneca
Design of a Phase 1 Virtual Hybrid Study of AZD7594, an Inhaled Non-Steroidal, Selective Glucocorticoid Receptor Modulator, in Adolescents with Asthma (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area C) - Mar 15, 2020 - Abstract #ATS2020ATS_7106;
P2b
For the first time, we will run a virtual hybrid clinical trial concept, adapting the trial around the patient by (Figure);● Home nursing visits to perform PK-sampling, spirometry and plasma cortisol as pharmacodynamic (PD) assessments and safety evaluation through physical examination, electrocardiogram vital signs, adverse events and laboratory measurements.● Telemedicine visits through a digital platform for real time video consultations with the physician at study site, as well as capturing daily diary data regarding SABA use and ACQ-5, reading and signing informed consent form, visit scheduling and caregiver/patient end of study evaluation.● Remote PK and PD through a finger-prick micro-sampling device will be explored, with the aim of reducing lengthy and burdensome blood sampling in future trials.Conclusion The results of this study will characterize the PK, PD and safety of AZD7594 in adolescents with GINA 2 asthma. The hybrid virtual study concept will provide detailed insight into the feasibility of similar designs in this age group.
- || velsecorat (AZD7594) / AstraZeneca
Trial completion: A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects. (clinicaltrials.gov) - Dec 16, 2019
P1, N=24, Completed, Sponsor: AstraZeneca
The hybrid virtual study concept will provide detailed insight into the feasibility of similar designs in this age group. Active, not recruiting --> Completed
- |||| velsecorat (AZD7594) / AstraZeneca
Trial completion: GRANIT: A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects (clinicaltrials.gov) - Nov 19, 2019
P2b, N=808, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | velsecorat (AZD7594) / AstraZeneca
Trial completion date, Trial primary completion date: AMBER: A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma (clinicaltrials.gov) - Nov 15, 2019
P1, N=24, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Mar 2020 --> Jun 2020
- || velsecorat (AZD7594) / AstraZeneca
Enrollment closed: A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects. (clinicaltrials.gov) - Nov 15, 2019
P1, N=24, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Mar 2020 --> Jun 2020 Recruiting --> Active, not recruiting
- | velsecorat (AZD7594) / AstraZeneca
Enrollment open: A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects. (clinicaltrials.gov) - Oct 7, 2019
P1, N=24, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | velsecorat (AZD7594) / AstraZeneca
Enrollment closed: GRANIT: A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects (clinicaltrials.gov) - Aug 28, 2019
P2b, N=808, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | velsecorat (AZD7594) / AstraZeneca
New P1 trial: A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects. (clinicaltrials.gov) - Aug 28, 2019
P1, N=24, Not yet recruiting, Sponsor: AstraZeneca
- | velsecorat (AZD7594) / AstraZeneca
Enrollment open: AMBER: A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma (clinicaltrials.gov) - Jul 29, 2019
P1, N=24, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | velsecorat (AZD7594) / AstraZeneca
Trial completion: Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594 (clinicaltrials.gov) - Jul 24, 2019
P1, N=6, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | velsecorat (AZD7594) / AstraZeneca
Enrollment closed: Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594 (clinicaltrials.gov) - Jul 5, 2019
P1, N=6, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || velsecorat (AZD7594) / AstraZeneca
New P1 trial: Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594 (clinicaltrials.gov) - Jun 27, 2019
P1, N=6, Recruiting, Sponsor: AstraZeneca
- | AZD7594 / AstraZeneca
Clinical, P2a data, Journal: Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial. (Pubmed Central) - Jun 19, 2019
P2
Two-week treatment with AZD7594 demonstrated a favorable risk-benefit profile in patients with mild to moderate asthma. Further clinical studies are needed to fully characterize AZD7594.
- || velsecorat (AZD7594) / AstraZeneca
New P1 trial: AMBER: A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma (clinicaltrials.gov) - Jun 5, 2019
P1, N=24, Not yet recruiting, Sponsor: AstraZeneca
- |||| velsecorat (AZD7594) / AstraZeneca
Enrollment open: GRANIT: A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects (clinicaltrials.gov) - Feb 5, 2019
P2b, N=714, Recruiting, Sponsor: AstraZeneca
Further clinical studies are needed to fully characterize AZD7594. Not yet recruiting --> Recruiting
- |||||| velsecorat (AZD7594) / AstraZeneca
New P2b trial: GRANIT: A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects (clinicaltrials.gov) - Aug 9, 2018
P2b, N=714, Not yet recruiting, Sponsor: AstraZeneca
- | velsecorat (AZD7594) / AstraZeneca, abediterol (AZD-0548) / AstraZeneca
Trial completion: A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants (clinicaltrials.gov) - Apr 12, 2017
P1, N=14, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | velsecorat (AZD7594) / AstraZeneca
Trial completion: A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers (clinicaltrials.gov) - Mar 28, 2017
P1, N=12, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- velsecorat (AZD7594) / AstraZeneca
Enrollment closed, Enrollment change: A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers (clinicaltrials.gov) - Feb 1, 2017
P1, N=12, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=18 --> 12
- velsecorat (AZD7594) / AstraZeneca, abediterol (AZD-0548) / AstraZeneca
Enrollment closed, Enrollment change: A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants (clinicaltrials.gov) - Feb 1, 2017
P1, N=14, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | N=18 --> 12 Recruiting --> Active, not recruiting | N=32 --> 14
- velsecorat (AZD7594) / AstraZeneca, abediterol (AZD-0548) / AstraZeneca
Enrollment open: A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants (clinicaltrials.gov) - Dec 17, 2016
P1, N=32, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | N=32 --> 14 Not yet recruiting --> Recruiting
- velsecorat (AZD7594) / AstraZeneca
Enrollment open: A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers (clinicaltrials.gov) - Dec 4, 2016
P1, N=18, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | velsecorat (AZD7594) / AstraZeneca, abediterol (AZD-0548) / AstraZeneca
New P1 trial: A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants (clinicaltrials.gov) - Nov 18, 2016
P1, N=32, Not yet recruiting, Sponsor: AstraZeneca
- | velsecorat (AZD7594) / AstraZeneca
New P1 trial: A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers (clinicaltrials.gov) - Oct 11, 2016
P1, N=18, Not yet recruiting, Sponsor: AstraZeneca
- | velsecorat (AZD7594) / AstraZeneca
Trial completion: A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects (clinicaltrials.gov) - Jun 21, 2016
P1, N=21, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| velsecorat (AZD7594) / AstraZeneca
Trial completion, Enrollment change: A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men (clinicaltrials.gov) - Jun 21, 2016
P1, N=59, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Suspended --> Completed | N=36 --> 59
- velsecorat (AZD7594) / AstraZeneca
Trial suspension: A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men (clinicaltrials.gov) - May 11, 2016
P1, N=36, Suspended, Sponsor: AstraZeneca
Suspended --> Completed | N=36 --> 59 Recruiting --> Suspended
- velsecorat (AZD7594) / AstraZeneca
Trial primary completion date: A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects (clinicaltrials.gov) - Apr 18, 2016
P1, N=24, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Suspended Trial primary completion date: Mar 2016 --> Jun 2016
- |||| velsecorat (AZD7594) / AstraZeneca
Trial completion, Enrollment change: A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma (clinicaltrials.gov) - Feb 17, 2016
P2, N=110, Completed, Sponsor: AstraZeneca
Trial primary completion date: Mar 2016 --> Jun 2016 Active, not recruiting --> Completed | N=48 --> 110
- velsecorat (AZD7594) / AstraZeneca
Enrollment closed: A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects (clinicaltrials.gov) - Feb 17, 2016
P1, N=24, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed | N=48 --> 110 Recruiting --> Active, not recruiting
- velsecorat (AZD7594) / AstraZeneca
Enrollment open: A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects (clinicaltrials.gov) - Jan 24, 2016
P1, N=24, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- velsecorat (AZD7594) / AstraZeneca
Enrollment open: A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men (clinicaltrials.gov) - Jan 24, 2016
P1, N=36, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | velsecorat (AZD7594) / AstraZeneca
New P1 trial: A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects (clinicaltrials.gov) - Jan 7, 2016
P1, N=24, Not yet recruiting, Sponsor: AstraZeneca
- | velsecorat (AZD7594) / AstraZeneca
New P1 trial: A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men (clinicaltrials.gov) - Jan 4, 2016
P1, N=36, Not yet recruiting, Sponsor: AstraZeneca
- | velsecorat (AZD7594) / AstraZeneca
Enrollment closed: A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma (clinicaltrials.gov) - Nov 16, 2015
P2, N=48, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | velsecorat (AZD7594) / AstraZeneca
Enrollment open: A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma (clinicaltrials.gov) - Jul 23, 2015
P2, N=48, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | velsecorat (AZD7594) / AstraZeneca
New P2 trial: A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma (clinicaltrials.gov) - Jun 24, 2015
P2, N=48, Not yet recruiting, Sponsor: AstraZeneca
- || velsecorat (AZD7594) / AstraZeneca
Enrollment change: To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 (clinicaltrials.gov) - Jun 18, 2013
P1, N=73, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting N=108 --> 73